Women's Health · LP-100
Clotrimazole Vaginal tablet
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-100Women's Health
- Generic identity
- ClotrimazoleVaginal tablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-100
- Generic ingredient
- Clotrimazole
- Dosage form
- Vaginal tablet
- Proposed strength
- 100 mg; 200 mg; 500 mg
- Proposed pack
- Blister; single or 6-tablet pack
- Portfolio category
- Women's Health
About Clotrimazole
Clotrimazole is an antifungal ingredient used in several local formulations. A vaginal tablet, also called a pessary in some markets, is designed for a vaginal route and should not be confused with an oral tablet or skin cream. The relevant educational context is vaginal candidiasis when the diagnosis and patient circumstances support that treatment. Similar symptoms can have other infectious or non-infectious causes.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Clinical review is particularly relevant for a first episode, recurrent symptoms, pregnancy, unusual discharge, fever, pelvic pain or bleeding. These findings may require testing or another management pathway. Different pessary strengths and pack sizes correspond to distinct authorized presentations; they are not a prescribing schedule in this catalogue. The cited NHS information explains the ingredient and local formulations, but it does not authorize a proposed Luang Pharma product.
Important safety considerations
Local burning, irritation, swelling or discomfort can occur, and rare serious allergy requires urgent help. Vaginal clotrimazole products can affect latex barrier contraceptives, so the actual leaflet must be checked for precautions. Some medicines, including tacrolimus, can require interaction review with vaginal preparations. Do not swallow a vaginal tablet. Pregnancy and persistent symptoms require appropriate professional advice instead of repeated self-treatment.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The entry combines several vaginal-tablet strengths and single or multi-tablet packs. Each approved presentation needs its own clear route marking, leaflet and pack configuration. Any applicator, excipients and suitability during pregnancy must be confirmed for that product.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Confirm diagnosis, recurrence, pregnancy status, symptoms needing examination, interactions and contraceptive precautions. Refer to the exact authorized vaginal formulation and local clinical guidance.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Clotrimazole
- Dosage form / presentation
- Vaginal tablet
- Catalogue strength
- 100 mg; 200 mg; 500 mg
- Catalogue pack
- Blister; single or 6-tablet pack
- Portfolio category
- Women's Health
Layer 02
Unresolved product-specific fields
- Exact release/coating/scoring characteristics and formulation-specific administration instructions require controlled product documentation where applicable.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- NHS: clotrimazolepublic health service medicine information
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled product master/specification confirming the exact ingredient identity, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-100, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-100.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.